Verismo Therapeutics Inc. has entered into a licensing agreement with the University of Pennsylvania for worldwide exclusive rights for two newly discovered anti-CD19 binders, the result of a sponsored research agreement between the two parties.

Day One Biopharmaceuticals Inc. has entered into an exclusive, worldwide license agreement and research collaboration with Sprint Bioscience...

Celloram Inc. has signed a licensing agreement with Genfit SA to advance Celloram’s first-in-class inflammasome inhibitor, CLM-022. The agreement grants Genfit exclusive global rights to develop CLM-022 in liver disease indications.

Alexion, Astrazeneca Rare Disease, part of Astrazeneca plc, has entered a definitive purchase and license agreement for a portfolio of preclinical gene therapy programs and enabling technologies from Pfizer Inc.

Riparian Pharmaceuticals Inc., a Viva Biotech Holdings Group portfolio company, has entered into an exclusive license agreement and research agreement with Pfizer Inc. in cardiovascular disease.

Maxcyte Inc. and Vittoria Biotherapeutics Inc. have signed a strategic platform license agreement for use of Maxcyte’s Flow Electroporation technology and Expert platform by Vittoria Biotherapeutics. Under the agreement, Vittoria will obtain nonexclusive clinical and commercial rights to use Maxcyte’s Flow Electroporation technology and Expert platform, and will pay Maxcyte platform licensing fees and program-related revenue.

Fulcrum Therapeutics Inc. has entered into a worldwide, exclusive license agreement with Camp4 Therapeutics Corp. to advance the discovery, development and commercialization of new therapeutic agents against an undisclosed target for the potential treatment of Diamond-Blackfan anemia (DBA).

Hillstream Biopharma Inc. has signed an exclusive agreement with Applied Biomedical Science Institute (ABSI) to license technology for human antibodies targeting novel HER2 and HER3 conformational epitopes. The goal is to develop proprietary multiformat biologics, including bispecific antibodies and antibody-drug conjugates (ADCs).

Sangamo Therapeutics Inc. and Voyager Therapeutics Inc. have entered into a definitive license agreement for a potential treatment for prion disease.